ADOCY:OTC-Adocia SA ADR (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 11.80

Change

0.00 (0.00)%

Market Cap

USD 0.10B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

ADOCY Stock Forecast & Price:
Based on the Adocia SA ADR stock forecasts from 0 analysts, the average analyst target price for Adocia SA ADR is not available over the next 12 months. Adocia SA ADR’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Adocia SA ADR is Bearish, which is based on 1 positive signals and 8 negative signals. At the last closing, Adocia SA ADR’s stock price was USD 11.80. Adocia SA ADR’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Adocia SA ADR
No recent average analyst rating found for Adocia SA ADR

About Adocia SA ADR (ADOCY:OTC)

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to o ...Read More

Company Website : https://www.adocia.com

Address : 115 Avenue Lacassagne, Lyon, France, 69003

Employees : 110

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.37

52 Week High : 11.80

52 Week Low : 11.80

200 Day Moving Average : 11.80

50 Day Moving Average : 11.80

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

+2.66 (+2.26%)

 USD267.54B 36.46 3.31
CMXHF CSL Limited

+5.05 (+2.55%)

 USD97.77B 40.73 27.99
CSLLY CSL Ltd

+0.59 (+0.59%)

 USD96.85B 41.72 27.99
GNMSF Genmab A/S

-11.70 (-2.59%)

 USD30.34B 37.88 3.53
WXIBF WuXi Biologics

N/A

 USD28.19B 51.38 5.10
WXXWY WuXi Biologics (Cayman) Inc

+0.17 (+1.37%)

 USD26.12B 45.85 5.10
ARGNF argenx SE

N/A

 USD21.19B N/A -20.63
UCBJF UCB SA

N/A

 USD15.38B 17.01 11.33
UCBJY UCB SA ADR

-0.21 (-0.52%)

 USD15.25B 16.84 11.33
SHJBF Shanghai Junshi Biosciences Co..

N/A

 USD13.48B N/A -4.02

ETFs Containing ADOCY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -34.99% 63% D 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.99% 63% D 41% F
Average Annual (5 Year Horizon)  
Capital Gain -8.77% 38% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.77% 37% F 19% F
Risk Return Profile  
Volatility (Standard Deviation) 20.36% 92% A- 83% B
Risk Adjusted Return -43.07% 29% F 16% F
Market Capitalization 0.10B 71% C- 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.60 47% F 35% F
Price/Book Ratio 11.22 26% F 11% F
Price / Cash Flow Ratio -5.22 72% C- 77% C+
EV/EBITDA -9.06 85% B 85% B
Management Effectiveness  
Return on Equity -361.38% 24% F 6% F
Return on Invested Capital -70.17% 32% F 13% F
Return on Assets -24.50% 62% D- 24% F
Debt to Equity Ratio -132.36% 88% B+ 96% A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.37 27% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector